GLADWIN, M.; KATO, G.; NOVELLI, E.
The first text to provide comprehensive coverage of sickle cell disease with both a research and clinical focus
Covering the genetic basis of the disease along with the most current work in gene editing, Sickle Cell Disease provides clinical features and diagnosis, as well as standards of therapy and future treatment options in children and adults. It explores rare and common cases, includes both domestic and internationally relevant topics, and covers psychosocial and supportive care. Free online updates available
Providing the latest guidelines for patient care, Sickle Cell Disease covers cardiopulmonary complications, new gene editing/gene therapy, and information for investigators in life sciences and in pharmaceutical drug development space. With chapters written by a "who's who" in the world of sickle cell disease research and treatment, this unparalleled resource combines state-of-the-art clinical diagnosis, quality care, management, and the evolution of science in one volume for the first time ever.
• Mark T. Gladwin, MD, is Professor and Chairman, Department of Medicine, University of Pittsburgh, and Director, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute.
• Gregory Kato, MD, is Professor of Medicine, Division of Hematology/Oncology, University of Pittsburgh, and Director, University of Pittsburgh's Sickle Cell Center of Excellence.
• Enrico Novelli, MD, is Associate Professor of Medicine, Division of Hematology/Oncology, University of Pittsburgh, and Director, University of Pittsburgh Medical Center's Adult Sickle Cell Disease Program.